- Home
- TCRX
as 07-26-2024 4:00pm EST
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 365.8M | IPO Year: | 2021 |
| Target Price: | $11.40 | AVG Volume (30 days): | 591.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.93 - $9.69 | Next Earning Date: | 08-08-2024 |
| Revenue: | $14,812,000 | Revenue Growth: | -14.47% |
| Revenue Growth (this year): | -61.94% | Revenue Growth (next year): | -58.01% |
Stock Insider Trading Activity of TScan Therapeutics Inc. (TCRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BARBERICH TIMOTHY J | TCRX | Director | Dec 18 '23 | Buy | $4.89 | 28,830 | $140,880.68 | 66,710 | SEC Form 4 |
| BARBERICH TIMOTHY J | TCRX | Director | Dec 18 '23 | Buy | $4.97 | 317 | $1,575.01 | 67,027 | SEC Form 4 |
| Klencke Barbara | TCRX | Director | Dec 14 '23 | Buy | $5.08 | 5,000 | $25,400.00 | 30,000 | SEC Form 4 |
Latest TScan Therapeutics Inc. News
TCRX Breaking Stock News: Dive into TCRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
TScan Therapeutics Decline Means Insider Profits Down To US$54k
Zacks
a month ago
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
MT Newswires
a month ago
TScan Therapeutics Names Stephen Biggar Board Chair
GlobeNewswire
a month ago
TScan Therapeutics Announces Updates to its Board of Directors
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
2 months ago
New Zealand scraps plan to tax livestock burps, farts
Compare TCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCRX TScan Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.